Cabarrus County Fair Grounds are at 4759 NC Highway ... p.m. Join Downtown Concord for Art Walk on Union hosted in partnership with @concorddowntown and sponsored by Eli Lilly and Company.

Eli Lilly exhibits robust revenue growth, with Q2 revenue surging by 36%, driven by new products contributing nearly $3.5 billion compared to the same period last year (David Ricks, Chair and CEO).

Eli Lilly (LLY) Stock Price Prediction in 2025 The current Wall Street consensus 1-year target of Eli Lilly stock is $898, which is -2.67% higher than today’s price of $922.59. Of the 26 ...

Eli Lilly said the Food and Drug Administration approved its treatment for moderate-to-severe eczema that isn't well controlled despite treatment with topical prescription therapies. The treatment ...

The FDA has approved an Eli Lilly drug that offers a new biologic treatment option with a dosing schedule that’s less burdensome for patients. The regulatory decision announced late Friday ...

On Friday, the U.S. Food and Drug Administration approved Eli Lilly's eczema drug for use in adults and children 12 and older. The medication is an injectable branded Ebglyss and will be ...

An FDA approval has officially lifted the curtain on a blockbuster market showdown between Novartis and Eli Lilly in early breast cancer. The FDA has greenlighted Novartis’ Kisqali, used in ...

Also Read: Eli Lilly Pumps $800M Into Irish Operations To Meet Skyrocketing Demand For Mounjaro, Zepbound. The recommended initial starting dose of Ebglyss is 500 mg (two 250 mg injections ...

Three years after establishing an immunology unit, Eli Lilly has gained its third FDA approval in the specialty area as the U.S. regulator has signed off on IL-13 inhibitor Ebglyss to treat atopic ...

(Reuters) -Eli Lilly said on Friday the U.S. Food and Drug Administration approved its eczema drug for use in adults and children above 12 years old. The drug, which is an injectable medicine and ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against Morgan Stanley’s other stock picks. The tail end of 2024 is seeing a market shift in the ...